Evotec SE

Informe acción NasdaqGS:EVO

Capitalización de mercado: US$953.9m

Evotec Dividendos y recompras

Dividendo controles de criterios 0/6

Evotec no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

0.2%

Rendimiento de la recompra

Rendimiento total para el accionista0.2%
Rendimiento futuro de los dividendos0%
Crecimiento de los dividendosn/a
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Ratio de pagon/a

Últimas actualizaciones de dividendos y recompras

Recent updates

Seeking Alpha • Jul 23

Evotec: Recovery Seems To Be Beginning

Summary Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis. Risks are significant, but Evotec's growth prospects and current valuation justify maintaining my position for potential outsized returns over several years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Evotec: Some Recovery Has Come, But Much More Is Expected

Summary Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. I maintain a price target of €20/share ($11/share for the Nasdaq ticker), viewing Evotec as a speculative investment with a risk/reward-adjusted upside. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Evotec: Weak Performance, But Long-Term Potential Is There

Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Evotec: Still A Speculative Buy After A Significant Decline

Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping down of the CEO have also contributed to the decline in share price. I am still saying "Spec BUY", but with care. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs for forming new life science companies, Evotec said in a statement on Monday. TIAP and Evotec created LAB150 in 2017 to accelerate Toronto's academic research into market-ready products. Amgen will provide financial support for chosen LAB150 projects and mentorship from its drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment, Evotec noted. "Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation,” said TIAP President and CEO Parimal Nathwani.
Seeking Alpha • Sep 20

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-based unit Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of phase 1 first-in-human (FIH) trials, the company said in a Sept. 20 press release. To enable rapid development, Just - Evotec will use its data-driven, automated biologics technology platform J.DESIGN and continuous manufacturing at its J.POD Redmond, Washington (U.S.) facility. Evotec will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). EVO -5.24% to $9.41 premarket Sept. 20
Seeking Alpha • Aug 25

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec said in an Aug. 25 press release that the contract was signed on Aug. 24 at a purchase price of €1. Evotec added it intends to invest in the coming years to establish the facility as a European center of excellence for rare disease drug substance manufacturing. Evotec said Central Glass will now operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). Central Glass is located on a pharmaceutical manufacturing campus in Halle/Westphalia and has a team of ~60 chemical manufacturing experts. The transaction is expected to close on Nov. 1, subject to conditions. Evotec noted that earnings accretion is expected to be achieved by 2023/24. EVO +1.11% to $11.87 premarket Aug. 25
Seeking Alpha • Aug 10

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec (NASDAQ:EVO) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences (NASDAQ:ALPN) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303. Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington. EVO -10.15% to $12.66 premarket Aug. 10
Seeking Alpha • Jul 06

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Boehringer Ingelheim, Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision medicine approach from diagnosis to cure, was funded with €40M in total with Boehringer Ingelheim investing €30M and Evotec and bioMérieux funding €5M each, according to the companies' July 6 press release. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results," said bioMérieux Chairman and CEO Alexandre Mérieux. Boehringer's participation in Aurobac is part of a wider pandemic preparedness initiative, which includes a €50M investment in AMR. Boehringer Ingelheim Venture Fund has committed to invest up to €12M in AMR infection companies.

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de EVO han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de EVO han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Evotec vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de EVO con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (EVO)n/a
Suelo de mercado 25% (US)1.4%
Techo de mercado 25% (US)4.3%
Media de la industria (Life Sciences)0.8%
Analista de previsiones (EVO) (hasta 3 años)0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de EVO en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de EVO en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de EVO para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que EVO no ha comunicado ningún pago.

Descubre empresas que pagan buenos dividendos

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/17 17:08
Precio de las acciones al final del día2026/05/15 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Evotec SE está cubierta por 23 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc